Peginterferon α-2a and ribavirin treatment of patientswith haemophilia and hepatitis C virus infection: A single-centre study of 367 cases

Liver International

Volumn 30, Issue 8, 2010, Pages 1173-1180

  Alavian, Seyed Moayed ^a   Tabatabaei, Seyed Vahid ^a   Keshvari, Maryam ^b   Behnava, Bita ^a   Miri, Seyyed Mohammad ^a   Elizee, Pegah Karimi ^b   Lankarani, Kamran Bagheri ^c  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b IRANIAN BLOOD TRANSFUSION ORGANIZATION   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Congenital bleeding disorder; Haemophilia; HCV; Peginterferon a 2a; Ribavirin

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ALOPECIA; ANXIETY; ARTHRALGIA; ARTICLE; BODY MASS; CHILL; COUGHING; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRY SKIN; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; GENOTYPE; HEADACHE; HEMOPHILIA A; HEMOPHILIA B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSOMNIA; IRRITABILITY; LETHARGY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; MYALGIA; NEUTROPENIA; PREDICTOR VARIABLE; PRURITUS; RELAPSE; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VON WILLEBRAND DISEASE; WEIGHT REDUCTION;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GENOTYPE; HEMOPHILIA A; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; IRAN; ODDS RATIO; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL;

EID: 79951639515     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02296.x     Document Type: Article

References (45)

1. Ahmadipour MH, Alavian SM, Amini S, Azadmanesh K. Hepatitis C virus genotypes. Hepat Mon 2005; 5: 77-82.
2. Arens M. Clinically relevant sequence-based genotyping of HBV, HCV, CMV, and HIV. J Clin Virol 2001; 22: 11-29.
3. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29: 74-81.
4. Goodnough LT, Brecher ME, Kanter MH, Jp A. Transfusion medicine: blood transfusion. NEJM 1999; 340: 438-47.
5. Samimi-Rad K, Shahbaz B. Hepatitis C virus genotypes among patients with thalassemia and inherited bleeding disorders in Markazi province, Iran. Haemophilia 2007; 13: 156-63.
6. Bahakim H, Bakir TMF, Arif M, Ramia S. Hepatitis C virus antibodies in high-risk Saudi groups. Vox Sanguinis 1991; 60: 162-4.
7. Fried MW. Management of hepatitis C in the hemophilia patient. Am J Med 1999; 107: 85S-9S.
8. Brettler DB, Alter HJ, Dienstag JL, Forsberg AD, Levine PH. Prevalence of hepatitis C virus antibody in a cohort of hemophilia patients. Blood 1990; 76: 254-6.
9. Eyster ME, Fried MW, Di Bisceglie AM, Goedert JJ. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study. Blood 1994; 84: 1020-3.
10. Kumar A, Kulkarni R, Murray DL, et al. Serologic markers of viral hepatitis A, B, C, and D in patients with hemophilia. J Med Virol 1993; 41: 205-9.
11. Sharifi-Mood B, Eshghi P, Sanei-Moghaddam E, Hashemi M. Hepatitis B and C virus infections in patients with hemophilia in Zahedan, southeast Iran. Saudi Med J 2007; 28: 1516-9.
12. Berenguer J, Alvarez-Pellicer J, Martin PM, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009; 50: 407-13.
13. Singal AK, Singh A, Jaganmohan S, et al. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 2010; 8: 192-9.
14. Breitenstein S, Dimitroulis D, Petrowsky H, et al. Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg 2009; 96: 975-81.
15. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-13.
16. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-93.
17. Awad T, Thorlund K, Hauser G, et al. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology 2010; 51: 1176-84.
18. Alavian SM, Behnava B, Tabatabaei SV. Comparative efficacy and safety of peginterferon alpha-2a vs. 2b for treatment of chronic HCV infection; a meta-analysis. Hepat Mon 2010; 10: 121-31.
19. Jensen DM, Marcellin P, Freilich B, et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med 2009; 150: 528-40.
20. Shire NJ, Horn PS, Rouster SD, et al. HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1-coinfected patients with hemophilia. Hepatology 2006; 44: 1146-57.
21. Alavian SM, Miri SM, Keshvari M, et al. Distribution of hepatitis C virus genotype in Iranian multiply transfused patients with thalassemia. Transfusion 2009; 49: 2195-9.
22. Franchini M, Mengoli C, Veneri D, et al. Treatment of chronic hepatitis C in haemophilic patients with interferon and ribavirin: a meta-analysis. J Antimicrob Chemother 2008; 6: 1191-200.
23. Mancuso ME, Rumi MG, Santagostino E, et al. High efficacy of combined therapy with pegylated interferon plus ribavirin in patients with hemophilia and chronic hepatitis C. Haematologica 2006; 91: 1367-71.
24. Posthouwer D, Fischer K, De Heusden N, Mauser-Bunschoten EP. Pegylated interferon and ribavirin combination therapy for chronic hepatitis C in patients with congenital bleeding disorders: a single-centre experience. Haemophilia 2007; 13: 98-103.
25. Posthouwer D, Yee TT, Makris M, et al. Antiviral therapy for chronic hepatitis C in patients with inherited bleeding disorders: an international, multicenter cohort study. J Thromb Haemost 2007; 5: 1624-9.
26. Katsarou O, Theodosiades G, Ioannidou P, et al. Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C in patients with congenital coagulation disorders. Acta Haematol 2008; 120: 63-9.
27. Ascione A, Luca MD, Tartaglione MT, et al. Peginterferon Alphalfa-2a plus ribavirin is more effective than peginterferon alpha-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology 2010; 138: 116-22.
28. Escudero A, Rodriguez F, Serra MA, et al. Pegylated alphainterferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study. J Gastroenterol Hepatol 2008; 23: 861-6.
29. Lee S, Kim IH, Kim SH, et al. Efficacy and tolerability of pegylated interferon-a(2a) plus ribavirin versus pegylated interferon-a(2b) plus ribavirin in treatment-naive chronic hepatitis C patients. Intervirology 2010; 53: 146-53.
30. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 146-52.
31. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-92.
32. Satapathy SK, Lingisetty CS, Proper S, Chaudhari S, Williams S. Equally poor outcomes to pegylated interferon-based therapy in African Americans and Hispanics with chronic hepatitis C infection. J Clin Gastroenterol 2010; 44: 140-5.
33. Rodriguez-Torres M, Jeffers LJ, Sheikh MY, et al. Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med 2009; 360: 257-67.
34. Sauleda S, Esteban JI, Altisent C, et al. Treatment with interferon plus ribavirin in anti-HIV negative patients with congenital coagulation disorders and chronic hepatitis C. Thromb Haemost 2000; 83: 807-10.
35. Fried MW, Peter J, Hoots K, et al. Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirin. Hepatology 2002; 36: 967-72.
36. Testino G, Sumberaz A, Ancarani AO, et al. Influence of body mass index, cholesterol, triglycerides and steatosis on pegylated interferon alfa-2a and ribavirin treatment for recurrent hepatitis C in patients transplanted for HCVand alcoholic cirrhosis. Hepatogastroenterology 2009; 56: 501-3.
37. Hsu CS, Liu CH, Liu CJ, et al. Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy. Antivir Ther 2009; 14: 45-54.
38. Al Ashgar H, Helmy A, Khan MQ, et al. Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4. Ann Saudi Med 2009; 29: 4-14.
39. KryczkaW, Zarebska-Michaluk D, ChrapekM. Assessment of selected clinical factors as predictors of response to combined interferon-alpha plus ribavirin therapy among patients with chronic hepatitis C. Med Sci Monit 2003; 9: 32-5.
40. Kaserer K, Fiedler R, Steindl P, et al. Liver biopsy is a useful predictor of response to interferon therapy in chronic hepatitis C. Histopathology 1998; 32: 454-61.
41. Keeffe EB. Chronic hepatitis C: management of treatment failures. Clin Gastroenterol Hepatol 2005; 3: S102-5.
42. Sagir A, Heintges T, Akyazi Z, et al. Relapse to prior therapy is the most important factor for the retreatment response in patients with chronic hepatitis C virus infection. Liver Int 2007; 27: 954-9.
43. Rodriguez-Torres M, Rodriguez-Orengo JF, Rios-Bedoya CF, et al. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy. J Clin Virol 2007; 38: 32-8.
44. Blanchette VS, Vorstman E, Shore A, et al. Hepatitis C infection in children with hemophilia A and B. Blood 1991; 78: 285-9.
45. Kanesaki T, Kinoshita S, Tsujino G, Yoshioka K, Ikegami N. Hepatitis C virus infection in children with hemophilia: characterization of antibody response to four different antigens and relationship of antibody response, viremia, and hepatic dysfunction. J Pediatr 1993; 123: 381-7.